2019 recipient: Dr Michelle Henderson
Dr Michelle Henderson, Children’s Cancer Institute, Sydney.
Project title: Targeting the NAD pathway as a new therapeutic strategy for high-risk leukaemia in children.
Rapidly dividing cancer cells can be dependent on a cellular biochemical called nicotinamide adenine dinucleotide (NAD) as an energy source. The Henderson laboratory discovered a new drug that blocks the production of NAD and has remarkably strong anti-leukaemia activity, even against the most aggressive subtypes of leukaemia.
This proposal aims to develop this drug as a novel therapeutic strategy for aggressive leukaemia in children, to ultimately improve their survival and minimise the side effects of treatment.Posted on February 5th, 2020
Developed by the Leukaemia Foundation in consultation with people living with a blood cancer, Leukaemia Foundation support staff, haematology nursing staff and/or Australian clinical haematologists. This content is provided for information purposes only and we urge you to always seek advice from a registered health care professional for diagnosis, treatment and answers to your medical questions, including the suitability of a particular therapy, service, product or treatment in your circumstances. The Leukaemia Foundation shall not bear any liability for any person relying on the materials contained on this website.